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Purpose: Asthma is a global health problem, and asthma prevalence in Asia is increasing. 
The REcognise Asthma and LInk to Symptoms and Experience Asia study assessed patients’ 
perception of asthma control and attitudes toward treatment in an accessible, real-life adult 
Asian population.
Patients and methods: An online survey of 2,467 patients with asthma from eight Asian 
countries/regions, aged 18–50 years, showed greater than or equal to two prescriptions in pre-
vious 2 years and access to social media. Patients were asked about their asthma symptoms, 
exacerbations and treatment type, views and perceptions of asthma control, attitudes toward 
asthma management, and sources of asthma information.
Results: Patients had a mean age of 34.2 (±7.4) years and were diagnosed with asthma for 
12.5 (±9.7) years. Half had the Global Initiative for Asthma-defined uncontrolled asthma. 
During the previous year, 38% of patients visited the emergency department, 33% were hospi-
talized, and 73% had greater than or equal to one course of oral corticosteroids. About 90% of 
patients felt that their asthma was under control, 82% considered their condition as not serious, 
and 59% were concerned about their condition. In all, 66% of patients viewed asthma control 
as managing attacks and 24% saw it as an absence of or minimal symptoms. About 14% of 
patients who correctly identified their controller inhalers had controlled asthma compared to 
6% who could not.
Conclusion: Patients consistently overestimated their level of asthma control contrary to what 
their symptoms suggest. They perceived control as management of exacerbations, reflective of 
a crisis-oriented mind-set. Interventions can leverage on patients’ trust in health care providers 
and desire for self-management via a new language to generate a paradigm shift toward symptom 
control and preventive care.
Keywords: asthma control, attitudes, perception
Introduction
Asthma is a global health problem and afflicted 334 million people worldwide in 
2014.1 It is more pronounced in parts of Asia, with 107 million sufferers in Southeast 
Asia and Western Pacific Region.2,3 Asthma also presents an economic cost: directly 
from hospitalization, treatment, and health care resources and indirectly from time 
lost from work, absenteeism, and premature death. In 2006, annual per patient direct 
cost of treatment ranged from USD108 to USD1,010 and constituted about 13.0% of 
the per capita GDP of countries in the Asia-Pacific.4 The cost of uncontrolled asthma 
was estimated to be 1.51 times that of the controlled disease4 and highlighted the 
need for better disease management if countries were to rein in the burden of caring 
for asthma patients.
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The 2012 REcognise Asthma and LInk to Symptoms and 
Experience (REALISE) survey was the largest appraisal of 
asthma patients in Europe.5 It showed that asthma control 
remained poor, and many patients perceived their asthma to 
be controlled and not serious despite the presence of symp-
toms and exacerbations. Furthermore, the optimal levels of 
asthma control achieved in clinical studies were often not 
replicated in real-life studies.6 Real-life studies revealed that 
asthma control when assessed according to international 
guidelines, such as the Global Initiative for Asthma (GINA),7 
was poor, and this was attributed to a complex interaction of 
guidelines and disease-, patient-, and doctor-related factors. 
Many patients felt least informed about the meaning of 
asthma control.6
While the overall prevalence of asthma in the Asian 
adult population (,5%) was lower than that in European 
populations, temporal studies of asthma prevalence in several 
developed Asian countries revealed a rising trend.8 Asthma 
control in Asia remained low despite the availability of effi-
cacious treatments. Earlier Asian studies of asthma patients 
were conducted through face-to-face or phone interviews and 
mainly addressed the burden of disease and patient’s reac-
tions to exacerbations.9–11 Where available, results showed 
that patients often overestimated their level of control and 
the situation has not improved in recent years.9 Earlier stud-
ies, including REALISE, used guidelines such as GINA to 
determine the level of control and did not seek the patient’s 
view of asthma control. This study, REALISE Asia, focused 
on patients’ perceptions of asthma control and their attitudes 
toward the disease and its treatment in an accessible, real-
life adult Asian population. It used an online survey to seek 
eligible respondents from validated consumer panels who 
used social media to broaden the coverage and reach to the 
patients.
Materials and methods
study design
REALISE Asia was a quantitative, online questionnaire-
based survey, which used a similar methodology as 
REALISE.5 The questionnaire from REALISE compared 
asthma symptoms and indicators of acute exacerbations 
across guideline-defined control levels7 and treatment types, 
investigated patients’ perceptions of asthma and attitudes 
toward asthma management, and identified that their sources 
of information had been cognitively tested and contained 
many validated elements. Our study’s working group, consist-
ing of practicing physicians and respiratory specialists, made 
revisions to the original questionnaire (permission granted, 
see Supplementary material), taking into consideration the 
local context (eg, the use of Weibo in People’s Republic of 
China) and asking the patients what the term “well-controlled 
asthma” meant to them. A field-test of the questionnaire was 
carried out with ten respondents per country prior to the 
survey. The results were analyzed, and minor amendments 
to the questionnaire were made for clarity.
survey population
Recruitment was done via a simple random sample of indi-
viduals aged 18–50 years from validated consumer panels12 
in People’s Republic of China, Hong Kong, Indonesia, Korea, 
Malaysia, Philippines, Singapore, and Taiwan. Email invites 
were sent to these individuals between December 2013 and 
March 2014 asking them to complete a 30-minute online 
questionnaire (Supplementary material). As there were no 
hospital/physician associations or referrals, approvals from 
institutional review boards were not required. The survey was 
conducted according to the International Chamber of Com-
merce/ European Society for Opinion and Market Research 
(ICC/ESOMAR) International Code on Market and Social 
Research,13 which sets out ethical principles for the conduct of 
market research. Patient informed consent was also obtained 
from each respondent.
The sample size was based on factors, including popu-
lation size and implementation cost, within 4%–8% error 
margin at 95% confidence level.14 The inclusion criteria 
were patients aged 18–50 years who were diagnosed with 
asthma, given greater than or equal to two asthma-related 
prescriptions in the past 2 years (to ensure that patients have 
active asthma), and had used social media. Respondents who 
were employed; had relatives employed in the health care, 
pharmaceutical, advertising, or market research industries; 
or had taken part in health care-related market research in 
the past 3 months were excluded.
Data collection
Respondents were allowed to answer the questionnaire once. 
Data quality checks included confirming responses and weed-
ing out unusual or illogical answers. Questions were designed 
to sieve out inconsistent or fraudulent responses, and 
some items were repeated for consistency and verification. 
Responses in the local language were interpreted and trans-
lated back to English. The working group reviewed and 
approved the translated materials.
Data analysis
Responses to the questionnaire were analyzed for the total 
eligible population. Answers relating to asthma symptoms 
and indicators of acute exacerbations were analyzed by 
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GINA-defined control levels7 and treatment type. Symptoms 
assessed were daytime asthma symptoms, night waking, 
activity limitation due to asthma, and reliever use15 during 
the past 7 days, and indicators were corticosteroids and 
antibiotics use, days off work, emergency department (ED) 
admissions, and hospitalizations. Perceptions assessed 
were asthma control (controlled/uncontrolled) and serious-
ness and concern of disease (on a 4-point scale). Attitudes 
were assessed on the patient’s agreement (on a 4-point scale) 
to statements on asthma. Patient’s views (in text) of asthma 
control were categorized by key messages and information 
sources by the frequency of selection. Tests of statistical 
significance were performed with Fisher’s exact test.16
Results
Demographics and clinical characteristics
A total of 71,002 individuals started the questionnaire. Of 
them, 49,409 who did not meet the inclusion criteria and 
18,672 who did not complete the survey were excluded. The 
most common exclusion reason was that they did not have 
asthma (75.6%, n=37,505). Among the eligible respondents, 
454 failed data quality checks and were excluded. The final 
analysis set contained 2,467 patients (Figure 1). The largest 
group was from People’s Republic of China (32.4%), fol-
lowed by South Korea (20.3%) and Taiwan (12.2%). Table 1 
presents their demographic and clinical characteristics. The 
mean age of asthma patients was 34.2 (±7.4) years. Both 
sexes were equally represented. They had been diagnosed 
with asthma for 12.5 (±9.7) years. Nine of ten patients were 
taking medication for their asthma, and 35.3% of them used 
a reliever and 16.5% used a controller. About 11.5% of the 
patients were current smokers.
Asthma control and symptoms
Using the GINA-defined criteria,7 17.8% (440), 32.5% (802), 
and 49.7% (1,225) of patients had controlled, partially con-
trolled, and uncontrolled asthma, respectively (Table 2). In 
the week before the survey, 38.2% of patients experienced 
asthma symptoms for .2 days, 64.2% indicated that symp-
toms interfered with their normal activities, and 71.2% had 
night awakenings due to asthma. Of the 1,887 patients who 
Table 1 Demographics and other clinical characteristics
Demographics and clinical characteristics Number of 
patients (N=2,467)
sex, n (%)
 Female 1,141 (46.3)
 Male 1,326 (53.7)
Mean age (standard deviation), years 34.2 (7.4)
Age range, years, n (%)
 18–25 345 (14.0)
 26–30 475 (19.3)
 31–35 624 (25.3)
 36–40 436 (17.7)
 41–45 424 (17.2)
 46–50 163 (6.6)
country or area, n (%)
 People’s republic of china 800 (32.4)
 south Korea 500 (20.3)
 Taiwan 300 (12.2)
 hong Kong 200 (8.1)
 singapore 200 (8.1)
 indonesia 166 (6.7)
 Malaysia 151 (6.1)
 Philippines 150 (6.1)
Years since asthma diagnosis, n (%)
 0–9 959 (38.9)
 10–19 632 (25.6)
 20–29 345 (14.0)
 30–39 117 (4.7)
 40–49 19 (0.8)
 Unknown/not sure 395 (16.0)
current smokers, n* (%) 284 (11.5)
comorbidities,† n (%)
 high BP/hypertension 711 (31.7)
 Depression 466 (20.8)
 rheumatoid arthritis 398 (17.7)
 Diabetes 309 (13.8)
 heart disease 223 (9.9)
 cOPD 122 (5.4)
 cancer 16 (0.7)
Treatment type,‡ n (%)
 none 302 (9.1)
 reliever/rescue inhaler 1,171 (35.3)
 controller inhaler 549 (16.5)
 Oral treatment (pill) 789 (23.8)
 TcM/TKM 250 (7.5)
 Others 257 (7.7)
Notes: *number of patients, n=1,075; †multiple selection allowed, number of 
responses, n=2,245; ‡multiple selection allowed, number of responses, n=3,318.
Abbreviations: BP, blood pressure; cOPD, chronic obstructive pulmonary disease; 
TcM, traditional chinese medicine; TKM, traditional Korean medicine.
Questionnaires
started (n=71,002)
Eligible respondents
who completed
questionnaire
(n=2,921)
Eligible respondents
included in final
survey (n=2,467)
Excluded
Excluded
•  Incomplete questionnaire (n=18,672)
•  Failed data cleaning QC (n=454)
•  Failed inclusion criteria (n=49,409)
•  Failed general screening criteria 
   (n=11,022)*
•  Did not have asthma (n=37,505)
•  Fewer than two prescriptions (n=837)
•  Do not use social media (n=29)
•  Did not give informed consent
   (n=16)
Figure 1 Survey flowchart.
Note: *Works or knows someone in related industry or took part in market 
research survey in the past 3 months; or age is not between 18 years and 50 years.
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owned a reliever inhaler, 45.2% used it greater than or equal 
to two times during the same period. In the year prior to the 
survey, 38.4% of patients visited the ED and 33.1% were 
hospitalized for asthma. Most (76.5%) patients required 
greater than or equal to one course of antibiotics to treat 
health problems related to asthma and 73.1% had greater 
than or equal to one course of corticosteroids for worsening 
asthma during the past year. Two of three patients missed 
work because of asthma. Patients with controlled asthma 
also experienced acute exacerbations in the previous year. 
They were mostly treated with antibiotics (56.1%) or oral 
corticosteroids (46.8%).
Asthma symptoms and indicators  
of exacerbations by treatment types
Table 3 shows the asthma symptoms and indicators of 
acute exacerbations by treatment types. Patients who were 
prescribed reliever-only or controller-only inhalers tended 
to have less symptoms compared to those on multiple 
therapies. Similar results were also obtained for the indica-
tors of exacerbations. About four to five of ten patients who 
were prescribed relievers had used them greater than two 
times a week.
Patients’ perceptions of asthma
Figure 2 describes the patients’ view of asthma control. Two-
thirds of patients related control to managing attacks: attacks 
are controllable with medical help (28.2%), no or reduced 
attacks (16.3%), prevention of attacks through medicines 
(10.6%), or lifestyle modification, eg, avoidance of trig-
gers (10.4%). About 24.1% saw it as minimal symptoms or 
impact on normal activities. Figure 3 relates the patients’ 
perception of asthma to their condition as defined by the 
GINA7 guidelines.
Table 2 Asthma symptoms and indicators of exacerbations overall and by GINA-defined control levels7
Overall  
(N=2,467)
GINA-defined asthma control
Controlled  
(n=440)
Partially controlled  
(n=802)
Uncontrolled 
(n=1,225)
% of total respondents 100 17.8 32.5 49.7
 Asthma symptoms (past 7 days)
  Daytime asthma symptoms, n (%)
   none 530 (21.5) 347 (78.9) 177 (22.1) 6 (0.5)
   2 days or less 995 (40.3) 93 (21.1) 584 (72.8) 318 (26.0)
   .2 days 942 (38.2) 0 41 (5.1) 901 (73.6)
  Activity limitation due to asthma, n (%)
   none 882 (35.8) 440 (100) 398 (49.6) 44 (3.6)
   $1 day 1,585 (64.2) 0 404 (50.4) 1,181 (96.4)
  night waking, n (%)
   none 710 (28.8) 440 (100) 253 (31.5) 17 (1.4)
   $1 day 1,757 (71.2) 0 549 (68.5) 1,208 (98.6)
  reliever needed for symptoms, n (%)
   not useda 949 (38.5) 377 (85.7) 400 (49.9) 172 (14.0)
   Two times or less 665 (27.0) 63 (14.3) 335 (41.8) 267 (21.8)
   .2 times 853 (34.6) 0 67 (8.4) 786 (64.2)
 Acute exacerbations (past 12 months)
  Oral steroid use for worsening asthma, n (%)
   not used 664 (26.9) 234 (53.2) 285 (35.5) 145 (11.8)
   $1 course 1,803 (73.1) 206 (46.8) 517 (64.5) 1,080 (88.2)
  Days off work/education, n (%)
   none 839 (34.0) 273 (62.0) 361 (45.0) 205 (16.7)
   $1 day 1,628 (66.0) 167 (38.0) 441 (55.0) 1,020 (83.3)
  Antibiotic use for an asthma-associated condition, n (%)
   not used 580 (23.5) 193 (43.9) 231 (28.8) 156 (12.7)
   $1 course 1,887 (76.5) 247 (56.1) 571 (71.2) 1,069 (87.3)
  emergency department visit due to asthma, n (%)
   none 1,520 (61.6) 372 (84.5) 612 (76.3) 536 (43.8)
   $1 visit 947 (38.4) 68 (15.5) 190 (23.7) 689 (56.2)
  Overnight hospitalization due to asthma, n (%)
   none 1,650 (66.9) 417 (94.8) 650 (81.0) 583 (47.6)
   $1 stay 817 (33.1) 23 (5.2) 152 (19.0) 642 (52.4)
Note: a580 patients did not own a reliever inhaler.
Abbreviation: ginA, global initiative for Asthma.
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Asthma condition is controllable/can be
controlled with medical help
“I directly ask for help when the symptoms
arise, either by using medication or by getting
medical treatment from medical team”.
“That I have sufficient medication in the event
of an attack and I am confident in the
medication I take”.
“Low frequency of relapses (attack) within a
month, or the condition can be controlled very
quickly using medication during relapses”.
“In case of attack, I can manage it by
medication”
“Being able to “ride out” the attack without
medication by controlling my breathing”
“Do exercise daily and take healthy food”.
“I can cope with asthma provided that I do not
make contact with the stimulants and I
maintain a healthy lifestyle”
“Still live an active life and act normal the way
other healthy people do”.
28.2
16.3
10.6
10.4
10.5
14.2
9.9
No/reduced attacks (within varying time
frames)
Attacks are controllable (with or w/o
medication)
Control asthma/prevent attacks through
lifestyle and avoiding triggers/taking
TCM
Agrees that my asthma is fully/partially
well controlled
Feels healthy and no/minimal impact on
normal activities
Asthma symptoms are minimal/non-
existent
0 5 10 15
Responses (%)
20 25 30
Figure 2 Perceptions of asthma control.
Notes: Supplementary material: Q1. Asthma sufferers have different definition ideas of what asthma control means to them. Please tell me what you think this phrase “well-
controlled asthma” means to you? Data are shown as percentage of respondents, n=2,275.
Abbreviations: TcM, traditional chinese medicine; w/o, without.
Table 3 Asthma symptoms and indicators of exacerbations by treatment types
Reliever inhaler  
only (n=415)
Controller inhaler  
only (n=74)
Reliever and controller  
inhalers only (n=246)
Oral pills plus  
inhaler(s) (n=538)
Asthma control and symptoms (past 7 days)
 GINA-defined control level, n (%)
  controlled 60 (14.5) 12 (16.2) 24 (9.8) 43 (8.0)
  Partially controlled 148 (35.7) 23 (31.1) 79 (32.1) 164 (30.5)
  Uncontrolled 207 (49.9) 39 (52.7) 143 (58.1) 331 (61.5)
 Daytime asthma symptoms, n (%)
  none 79 (19.0) 15 (20.3) 33 (13.4) 52 (9.7)
  $1 day 202 (48.7) 33 (44.6) 106 (43.1) 252 (46.8)
  $3 days 134 (32.3) 26 (35.1) 107 (43.5) 234 (43.5)
 Activity limitation due to asthma, n (%)
  none 143 (34.5) 27 (36.5) 68 (27.6) 140 (26.0)
  2 days or less 177 (42.7) 26 (35.1) 118 (48.0) 250 (46.5)
  .2 days 95 (22.9) 21 (28.4) 60 (24.4) 148 (27.5)
 night waking, n (%)
  none 118 (28.4) 19 (25.7) 60 (24.4) 93 (17.3)
  $1 day 297 (71.6) 55 (74.3) 186 (75.6) 445 (82.7)
 reliever needed for symptoms, n (%)
  not used 85 (20.5) 26 (35.1) 41 (16.7) 78 (14.5)
  Two times or less 176 (42.4) 17 (23.0) 82 (33.3) 217 (40.3)
  .2 times 154 (37.1) 31 (41.9) 123 (50.0) 243 (45.2)
Acute exacerbations (past 12 months)
 Oral steroid use for worsening asthma, n (%)
  none 142 (34.2) 20 (27.0) 78 (31.7) 56 (10.4)
  $1 course 273 (65.8) 54 (73.0) 168 (68.3) 482 (89.6)
 Antibiotic use for an asthma-associated condition, n (%)
  not used 105 (25.3) 25 (33.8) 59 (24.0) 59 (11.0)
  $1 course 310 (74.7) 49 (66.2) 187 (76.0) 479 (89.0)
 emergency department visit due to asthma, n (%)
  none 274 (66.0) 52 (70.3) 136 (55.3) 270 (50.2)
  $1 visit 141 (34.0) 22 (29.7) 110 (44.7) 268 (49.8)
 Overnight hospitalization due to asthma, n (%)
  none 283 (68.2) 55 (74.3) 159 (64.6) 279 (51.9)
  $1 stay 132 (31.8) 19 (25.7) 87 (35.4) 259 (48.1)
Abbreviation: ginA, global initiative for Asthma.
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When asked about their asthma, 89.1% of patients felt 
that it was under control and 81.5% felt that it was not serious 
(Table 4). Patients with uncontrolled asthma also felt no dif-
ferently (cf, 81.6% and 70.1%, respectively), but were more 
concerned about their condition than those with controlled 
asthma (58.7% vs 21.6%). For patients who experienced acute 
exacerbations requiring a visit to the ED or hospitalization, 
a smaller percentage compared to the overall population felt 
that their asthma was under control (83.5%, 82.5% vs 89.1%) 
or not serious (70.2%, 66.8% vs 81.5%). A higher percent-
age of them were also concerned about their asthma (60.3%, 
63.3% vs 45.6%).
Attitudes toward asthma and its 
management
Table 5 shows the patient’s attitudes toward asthma in daily 
life. They felt that they should fit in with people around them 
(88.7%) and did not want to be labeled as sick (85.0%) or 
Patient’s perception
of asthma control Perception does not match GINA
control level
Asthma is controlled 18%
2%
Controlled Partly controlled Uncontrolled
Number of patients =2,467
GINA-defined asthma  control level
31% 40%
9%
Asthma is not
controlled
Figure 3 Perception of vs GINA-defined asthma control.
Note: Data are shown as percentage of respondents, n=2,467; those who perceive that their asthma is controlled, n=2,198, and those who perceive that their asthma is 
not controlled, n=269.
Abbreviation: ginA, global initiative for Asthma.
Table 4 Patients’ perceptions of asthma by GINA-defined control levels7 and indicators of acute exacerbations
Overall  
(N=2,467)
GINA-defined asthma control Indicators of acute exacerbations
Controlled 
(n=440)
Partially 
controlled  
(n=802)
Uncontrolled 
(n=1,225)
Oral 
corticosteriods 
(n=1,803)
Emergency 
department 
visits (n=947)
Hospitalizations 
(n=817)
Perception of asthma control,* n (%)
 not controlled 269 (10.9) 7 (1.6) 36 (4.5) 226 (18.4) 233 (12.9) 156 (16.5) 143 (17.5)
 controlled 2,198 (89.1) 433 (98.4) 766 (95.5) 999 (81.6) 1,570 (87.1) 791 (83.5) 674 (82.5)
Perception of asthma seriousness,† n (%)
 not serious 2,011 (81.5) 421 (95.7) 731 (91.1) 859 (70.1) 1,405 (77.9) 665 (70.2) 546 (66.8)
 serious 456 (18.5) 19 (4.3) 71 (8.9) 366 (29.9) 398 (22.1) 282 (29.8) 271 (33.2)
concern about asthma,‡ n (%)
  not concerned 1,342 (54.4) 345 (78.4) 491 (61.2) 506 (41.3) 890 (49.4) 376 (39.7) 300 (36.7)
  concerned 1,125 (45.6) 95 (21.6) 311 (38.8) 719 (58.7) 913 (50.6) 571 (60.3) 517 (63.3)
Notes: *supplementary material: Q24a. Would you consider your asthma to be well controlled? controlled = yes; not controlled = no; †supplementary material: Q13. how 
serious do you consider your asthma to be at the moment? serious = very serious, fairly serious; not serious = not very serious, not at all serious; ‡supplementary material: 
Q15. To what extent are you concerned about your asthma? concerned = very concerned, fairly concerned; not concerned = not at all concerned.
Abbreviation: ginA, global initiative for Asthma.
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think about their asthma (70.0%). They also trusted their 
doctors and followed their instructions to manage their condi-
tion (86.8%). These percentages were similar across all the 
control levels. More patients with well-controlled asthma felt 
healthy and fit compared to those with uncontrolled asthma 
(82.0% vs 62.4%, P,0.01). They viewed their condition as 
different from sufferers with uncontrolled asthma (72.0% vs 
60.7%, P,0.01). When asked if they were worried about 
their condition in 10 years, more patients with uncontrolled 
asthma agreed compared to patients with controlled asthma 
(72.0% vs 42.7%, P,0.01).
About half of all patients agreed with statements that 
having inhalers was embarrassing or a nuisance. Patients 
with uncontrolled asthma, in particular, felt that it was an 
embarrassment (62.0%) or nuisance (52.2%) to use an inhaler 
or even carry one (56.7%) in public.
Attitudes toward controller inhalers
Most patients (52.8%) were aware of the need to use con-
troller inhaler regularly to control their asthma. When asked 
about their controller inhalers, 19.9% of patients identified 
them correctly, 31.3% incorrectly, and the rest did not know. 
Figure 4 shows the frequency of controller inhaler usage in 
the week prior to the survey. About 13.9% of patients used it 
daily and 42.8% used it on some days. Of those who answered 
correctly, 30.0% used them daily compared to 16.7% who 
could not (P,0.01). The 14.1% of patients who correctly 
named their controller inhalers had controlled asthma com-
pared to 6.0% of those who could not (P,0.01, Figure 5).
sources of asthma information
Nine-tenths of patients actively looked for information 
about asthma and one-third, at least once a week. Patients 
searched for information on asthma attack prevention, what 
makes asthma worse or can trigger attacks and what to do 
in an event of an asthma attack. Figure 6 shows the sources 
of asthma information. Online sources and health care 
professionals (HCPs) were cited in 42.5% and 38.4% of 
the responses, respectively. Health care professionals were 
considered trustworthy information sources and consisted 
of respiratory specialists (57.3% of patients), family physi-
cians/general practitioners (37.6%), and internal medicine 
specialists (33.2%). Other sources of information include 
health websites (38.6%), online health forums (35.9%), 
friends (32.2%), and family (29.5%).
Discussion
Our study showed that patient knowledge of asthma control 
and inhaler medication is low. Our patients viewed asthma 
control as being able to manage or relieve the exacerbations or 
attacks instead of preventing them. This was seen in the way 
they understood the concept of asthma control and reflected in 
Table 5 Patients’ attitude toward asthma in daily life
Overall  
(N=2,467)
GINA-defined asthma control7
Controlled 
(n=440)
Partially controlled  
(n=802)
Uncontrolled 
(n=1,225)
Patients who strongly agree or tend to agree with the following statements,* n (%)
  It is important that I fit in with people around me 2,189 (88.7) 401 (91.1) 724 (90.3) 1,064 (86.9)
  My doctor knows what is best for me and i try to follow what  
(s)he says
2,141 (86.8) 395 (89.8) 708 (88.3) 1,038 (84.7)
  Do not label me as a person who is sick 2,096 (85.0) 406 (92.3) 712 (88.8) 978 (79.8)
  I see myself as healthy and fit 1,729 (70.1) 361 (82.0) 603 (75.2) 765 (62.4)
  i just get on with my life, i do not think about my asthma 1,704 (69.1) 347 (78.9) 578 (72.1) 779 (63.6)
  i am not like other people with asthma 1,575 (63.8) 317 (72.0) 514 (64.1) 744 (60.7)
  i worry about what my asthma will be like in 10 years 1,493 (60.5) 188 (42.7) 423 (52.7) 882 (72.0)
  i live for today, rather than worry about tomorrow 1,484 (60.2) 285 (64.8) 475 (59.2) 724 (59.1)
  i have no time to think about my health as other things  
are more important
1,074 (43.5) 225 (51.1) 301 (37.5) 548 (44.7)
Patients who strongly agree or tend to agree with the following statements,† n (%)
  i feel embarrassed using my asthma inhaler in front of others 1,162 (52.5) 140 (40.2) 328 (44.5) 694 (62.0)
  I find it a real nuisance having to use my inhaler 1,189 (48.2) 187 (42.5) 363 (45.3) 639 (52.2)
  i feel embarrassed carrying my asthma inhaler around with me 1,294 (47.1) 177 (31.8) 357 (40.9) 760 (56.7)
  i ignore my doctor’s instructions about when and how often to  
take my medication (inhaler)
895 (36.3) 101 (23.0) 246 (30.7) 548 (44.7)
  I find my inhaler difficult to use 766 (31.1) 109 (24.8) 216 (26.9) 441 (36.0)
Notes: *supplementary material: Q2. To what extent do you agree or disagree with the following statements? Agree = tend to agree, strongly agree; †supplementary 
material: Q39. To what extent would you agree with the following statements? Agree = tend to agree, strongly agree.
Abbreviation: ginA, global initiative for Asthma.
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All 13.9% 42.8% 12.0% 24.3%
30.0% 35.7% 9.4% 24.9% 0.0%
16.7%
0%
I take it every day I take it some days, but other I do not
I used to take it, but now I do notI take it only when I have symptoms
I never take it 
10% 20% 30% 40% 50%
Respondents (%)
60% 70% 80% 90% 100%
53.3% 8.0% 21.7% 0.3%
6.9%
Answered correctly
Answered incorrectly
Figure 4 Frequency of use of controller inhalers.
Notes: supplementary material: Q36. Which statement best describes how you take your regular asthma treatment? This is your controller inhaler, which is usually brown, 
orange, red, purple, or pink; data on frequency of use are shown as percentage of respondents who use controller inhalers, n=1,072; those who correctly identified their 
inhalers, n=213, and those who incorrectly identified their inhalers, n=336. in all, 523 respondents could not identify their controller inhalers.
All controller inhalers
Name their controller inhalers correctly
Name their controller inhalers incorrectly
Controlled Partly controlled Uncontrolled
0% 10% 20% 30% 40% 50%
Respondents (%)
60% 70% 80% 90% 100%
9.1% 30.6% 60.3%
14.1% 35.2% 50.7%
6.0% 27.7% 66.4%
Figure 5 Knowledge of controller inhalers.
Notes: supplementary material: Q35i. Which of the following treatments do you currently take to help manage your asthma? (multiple selection of treatments allowed); 
supplementary material: Q35ii. Name of medication. Base: all respondents who are currently taking controller inhaler for managing asthma, as specified. If a respondent gives 
multiple names for controller inhaler, all the names for the controller inhaler must be correct = answered correctly; Otherwise = answered incorrectly. A list of controller 
inhalers (by country) was used to check if the name of medication provided by the respondent is correct; data are shown as percentage of respondents who use controller 
inhalers, n=1,072; those who correctly identified their inhalers, n=213, and those who incorrectly identified their inhalers, n=336. in all, 523 respondents could not identify 
their controller inhalers.
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their medication usage: reliever users outnumbered controller 
users by 2:1. In addition, about half the reliever users had a 
high frequency of use (greater than two times per week). This 
suggested that the level of control could have been underesti-
mated and the prescribed therapy was inadequate, not taken, 
or not appropriate. Asthma management was crisis-oriented 
through the widespread use of oral corticosteroids and anti-
biotics and emergency care – ED visits or hospitalization. 
Despite this, most patients held on to the belief that their 
asthma was not serious and under control. As a result, the 
level of control remained low and ,one-fifth of our patients 
achieved GINA-defined controlled asthma.
Many patients were concerned about their condition, espe-
cially those who had experienced acute exacerbations. The 
knowledge of controller inhalers was low, and only one-fifth 
of users could correctly identify their medication. Although 
they understood the preventive value of the inhaler and those 
who use it required the least hospitalizations or ED visits, 
many did not use it daily citing embarrassment and nuisance 
as reasons for not using them. Addressing these issues could 
improve treatment adherence as patients who correctly identi-
fied their inhaler medication had better asthma control.
Many patients expressed confidence in their HCPs and 
followed their instructions. HCPs are, thus, well placed to 
help their patients resolve issues about their disease and 
its management. A study of patient–physician communica-
tion and patients’ knowledge about asthma in Italy17 showed 
that 28.5% of general practitioners did not encourage patients 
to express doubts, expectations, or concerns and that 36.9% 
were unlikely to involve the patient in asthma management. 
Our patients used social media and searched online for infor-
mation, and their enquiries revealed a desire to self-manage 
their asthma. The Internet provides an excellent opportunity 
to augment the delivery of asthma management information 
through online channels, such as search engines, health-
related websites, and health forums.
Our survey relied on patients’ responses to the online 
questionnaire. These responses could not be clinically veri-
fied, and some patients might have inaccurately recalled 
certain events. Our respondents were patients who used 
social media and may not represent the cross-section of the 
asthmatic population. Compared to other Asian studies9–11 
that utilized face-to-face or phone interviews, the lower 
average age (34.2 years vs 40.5–45.0 years) and smaller 
female representation (46.3% vs 54.0%–57.5%) reflect 
the younger, male-predominant online population of our 
patients. REALISE5 patients also had a lower average age. 
However, clinical findings such as daytime symptoms 
Twitter 6.5
6.6
8.0
12.7
15.1
17.3
29.5
32.2
35.9
38.6
52.4
10.1
20.8
33.2
37.6
57.3
70605040
Responses (%)
3020100
YouTube
Weibo (China only)
Facebook
Pharmaceutical companies via their web site
Magazines, TV, or radio
Family
Friends
Online health forums
Specific disease or health websites
A search engine (eg, Google, Bing, Yahoo, Baidu
[People's Republic of China only])
Nurse
Pharmacist
IM
Family doctor/GP
Specialist respiratory doctor
Figure 6 sources of asthma information.
Notes: supplementary material: Q42i. if you were to look for information about asthma, which of the following would you use to help look for information on asthma? 
respondents may choose more than one option; data are shown as percentage of total responses, n=2,265.
Abbreviations: iM, internal medicine; gP, general practitioner.
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or seeking help at EDs was consistent with these studies 
(38.2% vs 23.9%–57.8% and 38.4% vs 40.0%–42.7%, 
respectively).5,9–11 Our study population and that of 
REALISE5 also had higher percentages of patients with 
controlled asthma (18%–20% vs 2%–3%).7–9 These two 
populations could have better access to asthma informa-
tion and put them at an advantage compared to the general 
asthma population. Segmentation of patients could provide 
further insights of their attitudes on asthma control, given 
the disparities in socioeconomic status of patients in dif-
ferent countries of multicultural Asia.
implications of results for asthma 
management policy and practice
Our study revealed a crisis-oriented approach to asthma man-
agement: high reliever and oral corticosteroid use, ED visits, 
and hospitalizations. This mind-set is similarly evident in how 
patients understand the concept of well-controlled asthma. 
Asthma management strategies need to evolve from relief 
to prevention. As patients are not always able to understand 
asthma control, HCPs are best positioned to educate patients 
on their condition, address the perception discrepancy, help 
patients overcome their anxieties, and influence their atti-
tudes toward treatment. Patient education, however, needs a 
new language to promote a shared understanding of asthma 
control between patients and physicians.
Conclusion
Patients consistently overestimate their level of asthma control 
rather than what their clinical symptoms suggest. This dis-
crepancy may be due to the patients’ perception that asthma 
control is about managing exacerbations instead of achieving 
a predefined level of symptom control. Patients also expressed 
concern about their asthma and sought information on how 
to manage their condition. Interventions to address patients’ 
perception of asthma control and attitudes toward the use of 
controller inhalers can leverage on their confidence in their 
HCPs and desire for better self-management. A new language 
to communicate the guideline-defined asthma control and pro-
mote the preventive use of controller medication is needed.
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